Alpha-Methyl Dopa for the Treatment of Hypertension

Weil, Max Harry; Barbour, Benjamin H.; Chesne, Robert B.

doi:10.1161/01.cir.28.2.165

Cited by 45 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In support of this assumption, resolution was sometimes reported to take place when administration of the drug was continued (Leonard et al 1965). Furthermore, readministration of alphamethyldopa did not always induce recurrence of the liver dysfunction (Weil et al 1963). In these large series, most patients with signs of liver dysfunction were entirely asymptomatic.…”

Section: Alpha-methy Ldopa Liver Injury Incidencementioning

confidence: 84%

“…The association of hepatocellular dysfunction with administration of alpha-methyldopa was first recorded by Gillespie in 1960. Among the first 1,500 recipients of the drug, only 1 1 instances of hepatic dysfunction occurred, an incidence of less than I % (Weil et al 1963). On the other hand, in a survey of studies published up to 1969 (Elkington et al 19691, an incidence of 6.3% of 823 patients was described.…”

Section: Alpha-methy Ldopa Liver Injury Incidencementioning

confidence: 99%

See 1 more Smart Citation

Liver Damage Due to Antihypertensive Drugs

Olsson¹

1979

Journal of Internal Medicine

View full text Add to dashboard Cite

Section: Alpha-methy Ldopa Liver Injury Incidencementioning

confidence: 84%

Section: Alpha-methy Ldopa Liver Injury Incidencementioning

confidence: 99%

Liver Damage Due to Antihypertensive Drugs

Olsson¹

1979

Journal of Internal Medicine

View full text Add to dashboard Cite

“…Most short-term studies on the effect of orally given a-methyldopa have shown a reduction in BP due to a reduction in total peripheral resistance, with no or only small changes in the cardiac output (CO) (1,10,11,13). In some acute studies clear reductions in CO have been found (8,10,12,14) but the drop in MAP has sometimes been relatively greater and, consequently, there has been a fall in the total peripheral resistance (8,10).…”

Section: Discussionmentioning

confidence: 99%

“…Before this treatment can be generally accepted, more information about the long-term hemodynamic effect of a-methyldopa would seem relevant. There are several studies on the hemodynamic effect of short-term therapy with this drug (1, 6, 7, 8, 10,11,12,13,14).…”

mentioning

confidence: 99%

Hemodynamic Changes in Long‐term Α‐methyldopa Therapy of Essential Hypertension

Lund‐Johansen

1972

Journal of Internal Medicine

View full text Add to dashboard Cite

Thirteen men with untreated essential hypertension in WHO stage I, all working, have been studied ambulatorily. Oxygen consumption, heart rate, cardiac output (Cardiogreen) and intra‐arterial brachial pressure were recorded at rest in supine and sitting position and during steady state work at 300, 600 and 900 kpm/min. The subjects were treated with α‐methyldopa as the sole drug for one year and the hemodynamic study was repeated. The reduction in the intra‐arterial pressure was usually due to a decrease in the cardiac output, with little effect on the calculated total peripheral resistance. The pressure reduction was greatest at rest and during light work. During submaximal exercise the differences between the hemodynamic parameters before and after therapy were small.

show abstract

“…The occurrence of altered liver function tests has been described as rare.80 31 Only 11 instances of hepatic dysfunction had been detected among the first 1,500 recipients of the drug, an incidence of less than 1%. 16 Subsequent studies in which routine liver function tests have been performed (table 2) revealed that the incidence of abnormal tests varies from 0% to 35% (mean, 6%). Variations in the timing, frequency, and type of biochemical studies probably account for this wide divergence.…”

Section: Discussionmentioning

confidence: 99%

Hepatic Injury Caused by L -Alpha-Methyldopa

Elkington

Schreiber

1969

Circulation

View full text Add to dashboard Cite

L -alpha-methyldopa (Aldomet)-induced liver disease is a relatively mild and uncommon complication of therapy with this drug. Most commonly it is characterized by a rise in serum alkaline phosphatase, glutamic oxaloacetic transaminase levels, and increased Bromsulphalein retention. Elevation of the serum bilirubin may occur. In its most benign form the condition is usually symptomless, but complaints, such as anorexia, abdominal pain, or pruritus, and signs, such as fever or hepatomegaly, may occur. Histologic changes similar to those of viral hepatitis have been observed. The condition is usually benign and remits on withdrawal of the drug. Progressively more mild exacerbations on readministration of the drug suggest that desensitization may be possible in patients who exhibit hepatic abnormalities. Its low and sporadic incidence is typical of a hypersensitivity reaction. It is suggested that routine liver function tests should be undertaken at intervals during therapy. The occasional occurrence of Aldomet-induced liver disease is no contraindication to the use of this antihypertensive agent.

show abstract

Alpha-Methyl Dopa for the Treatment of Hypertension

Cited by 45 publications

References 22 publications

Liver Damage Due to Antihypertensive Drugs

Liver Damage Due to Antihypertensive Drugs

Hemodynamic Changes in Long‐term Α‐methyldopa Therapy of Essential Hypertension

Hepatic Injury Caused by L -Alpha-Methyldopa

Contact Info

Product

Resources

About